PACS Group Inc. shares fell 8.18% and hit a 5-day low amid broader market declines, with the Nasdaq-100 down 2.23% and the S&P 500 down 2.13%.
Crewe Advisors disclosed in an SEC filing that it acquired 1,035,747 shares of PACS Group for an estimated $22.72 million, indicating strong confidence in the company's future growth prospects. This acquisition increased Crewe Advisors' total holdings in PACS Group to $82.45 million, reflecting a $67.19 million increase from the previous quarter. PACS shares have surged 184.9% over the past year, significantly outperforming the S&P 500, showcasing its competitive strength in the post-acute healthcare sector.
Despite the recent price drop, PACS Group's strong financial health, with a reported Q3 revenue of $1.34 billion and a 31% year-over-year increase, suggests that the company remains well-positioned for future growth.
Wall Street analysts forecast PACS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACS is 42.60 USD with a low forecast of 40.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast PACS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACS is 42.60 USD with a low forecast of 40.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.350
Low
40.00
Averages
42.60
High
47.00
Current: 34.350
Low
40.00
Averages
42.60
High
47.00
Truist
David MacDonald
Buy
downgrade
$48 -> $40
2026-01-05
Reason
Truist
David MacDonald
Price Target
$48 -> $40
AI Analysis
2026-01-05
downgrade
Buy
Reason
Truist analyst David MacDonald lowered the firm's price target on Pacs Group to $40 from $48 and keeps a Buy rating on the shares. Pacs Group is well-positioned into 2026 following the November conclusion of the Audit Committee investigation with committee recommendations having been or being implemented, the analyst tells investors in a research note.
UBS
NULL -> Buy
downgrade
$50 -> $42
2025-12-18
Reason
UBS
Price Target
$50 -> $42
2025-12-18
downgrade
NULL -> Buy
Reason
UBS resumed coverage of Pacs Group with a Buy rating with a price target of $42, down from $50. Pacs is well-positioned to take advantage of industry tailwinds that include an aging U.S. population, shifts to lower cost site of care settings, and a fragmented industry that provides ample acquisition opportunities of low performing facilities, the analyst tells investors in a research note. The current valuation reflects a few outstanding regulatory and legal issues and fundamentals are holding strong, the firm adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PACS
Unlock Now
JPMorgan
NULL
to
Overweight
initiated
$44
2025-12-17
Reason
JPMorgan
Price Target
$44
2025-12-17
initiated
NULL
to
Overweight
Reason
JPMorgan reinstated coverage of Pacs Group with an Overweight rating and $44 price target following a period of restriction. The firm believes Pacs has an attractive business model centered around acquiring underperforming skilled nursing facilities and capturing earnings through improvements to clinical, operational, and financial performance.
Truist
Buy
maintain
$32 -> $40
2025-12-12
Reason
Truist
Price Target
$32 -> $40
2025-12-12
maintain
Buy
Reason
Truist raised the firm's price target on Pacs Group to $40 from $32 and keeps a Buy rating on the shares. The firm remains bullish on the stock following upbeat management meetings highlighting the company's strong positioning, enhanced compliance/regulatory rigor post completion of the internal investigation, and attractive underlying trends, the analyst tells investors in a research note. Ongoing expansion activity further complements the solid core trends at Pacs, Truist added.
About PACS
PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. The Company is focused on delivering skilled nursing care through a portfolio of independently operated facilities. It also provides its independently operated facilities with a comprehensive suite of technology, support, and back-office services. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after they have been discharged from the hospital. This ecosystem ranges from higher acuity, higher-cost settings, such as long-term acute care hospitals and inpatient rehabilitation facilities, to lower acuity, lower-cost settings, such as assisted living facilities, and home health. The Company’s independent subsidiaries operate about 314 post-acute care and senior living facilities across 17 states, serving over 30,000 patients daily.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
